Fri, Aug 29, 2014, 10:21 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

  • biglabowski99 biglabowski99 Jan 21, 2013 6:34 PM Flag

    docihi asco gi

    Docihi will you be around tomorrow to review the esophageal and panc abstracts that are being released? I value your science interpretation.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • i will and hope to be helpful.

      • 1 Reply to docihi
      • eso - going nowhere and another indication that vis works on a limited list of cancers. pancreatic - the italian study was ok, but not overwhelming. we knew that vis is promising with stem cells in pancreatic adeno cancer. it is interesting that i have never heard another word that i can remember regarding vis and "cutting off the fuel supply" (glutamine). still nothing about vis/gem/abraxane in pancreatic; phii primary was due in december.

        this is of interest to me: "Abraxane/Gemcitabine Combination Improves Survival of Pancreatic Cancer Patients" (von hoff). we already knew that a nda was going to be submitted. of special interest is this line: " Significantly there was no increase in life-threatening toxicity. Other drug combinations that have demonstrated benefit have been limited by increased toxicities." does this mean the triple? maybe, maybe not.

 
CRIS
1.75+0.06(+3.55%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.